A study to evaluate the comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin (LS ± RBV) and ombitasvir/paritaprevir/ritonavir + dasabuvir (OPrD) ± RBV in HIV/HCV genotype 1 (GT1) veterans initiating hepatitis C virus therapy.

Trial Profile

A study to evaluate the comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin (LS ± RBV) and ombitasvir/paritaprevir/ritonavir + dasabuvir (OPrD) ± RBV in HIV/HCV genotype 1 (GT1) veterans initiating hepatitis C virus therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2017 Data from two prospective studies, one investigator sponsored (Ain et al.) and 1 registration trial (Isakov et al.), and three retrospective RWC (Deutsches Hepatitis C-Register, Madrid Coinfection Registry (Madrid-CoRe), and Veterans Affairs HCV Registry) used to assess effectiveness of the single tablet regimen of ledipasvir/sofosbuvir for 8 weeks in HCV genotype (GT) 1 patients with HIV/HCV coinfection; results presented at the 9th International AIDS Society Conference on HIV Science
    • 27 Dec 2016 New trial record
    • 30 Oct 2016 Results (n=996) presented at the IDWeek 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top